Jobs
-
According to Aradigm Corporation, the company has been informed that its MAA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (NCFBE) is likely… Read more . . .
-
Bryn Pharma (formerly Epi-Now) announced that it has signed a deal with Aptar Pharma for worldwide exclusive rights to use Aptar’s Bidose nasal delivery device for its BRYN-NDS1C intranasal epinephrine for the treatment of anaphylaxis.… Read more . . .
-
Circassia Pharmaceuticals has announced the US launch of Duaklir aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The FDA approved Duaklir Pressair in April 2019. Circassia acquired the US rights to Duaklir and Tudorza… Read more . . .
-
AZTherapies said that the company had closed a $26.3 million Series C preferred equity financing round that will fund completion of a Phase 3 trial of its ALZT-OP1 inhaled cromolyn/oral ibuprofen for the treatment of… Read more . . .
-
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Janssen’s Spravato esketamine nasal spray for use with either a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI)… Read more . . .
-
The 2019 iteration of the Drug Delivery to the Lungs conference, which will take place December 11-13, marks the event’s 30th year and will be the 15th DDL meeting held at the Edinburgh International Conference… Read more . . .
-
Boehringer Ingelheim has announced the initiation of a Phase 2 clinical trial of its BI 1265162 inhaled epithelial sodium channel (ENaC) inhibitor delivered via the Respimat SMI plus standard of care in cystic fibrosis patients.… Read more . . .
-
Respira Therapeutics has announced that United Therapeutics will end its collaboration with the company and will return all rights to Respira’s RT234 vardenafil DPI, which is in Phase 2 development for the relief of symptoms… Read more . . .
-
Contract manufacturer Experic, which offers a variety of services related to dry powder inhalers, has named Sherry Ann D’Iorio as Executive Director of Business Development. D’Iorio was most recently Senior Account Director of Business Development at… Read more . . .
-
According to Vectura, the English High Court has dismissed all claims in a “passing off” case brought by GlaxoSmithKline in which GSK charged that of Sandoz’s AirFluSal Forspiro DPI looks too similar to Seretide Accuhaler. Both inhalers and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany